Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.56 USD
Change Today -0.04 / -2.50%
Volume 125.6K
NNVC On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

nanoviricides inc (NNVC) Snapshot

Open
$1.62
Previous Close
$1.60
Day High
$1.63
Day Low
$1.55
52 Week High
06/24/14 - $4.77
52 Week Low
05/20/15 - $1.55
Market Cap
89.2M
Average Volume 10 Days
162.8K
EPS TTM
$-0.15
Shares Outstanding
57.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NANOVIRICIDES INC (NNVC)

Related News

No related news articles were found.

nanoviricides inc (NNVC) Related Businessweek News

No Related Businessweek News Found

nanoviricides inc (NNVC) Details

NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; DengueCide, a treatment against Dengue viruses; RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.

6 Employees
Last Reported Date: 02/23/15
Founded in 2005

nanoviricides inc (NNVC) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $275.0K
Chairman, President and Secretary
Total Annual Compensation: $275.0K
Chief Financial Officer
Total Annual Compensation: $108.0K
Compensation as of Fiscal Year 2014.

nanoviricides inc (NNVC) Key Developments

NanoViricides, Inc. announced delayed 10-Q filing

On 05/12/2015, NanoViricides, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

NanoViricides Announces Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Model

NanoViricides, Inc. reported dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the laboratory of Dr. Ken S. Rosenthal at Northeast Ohio Medical University where Dr. Rosenthal is now Professor Emeritus. Two of the anti-Herpes nanoviricides® reduced the extent of disease (morbidity) and mortality of the HSV-1 infected animals that were treated. These nanoviricides also reduced virus production in cell culture. Importantly, topical dermal treatment with these nanoviricides led to almost complete (>85%) survival of the infected mice in this animal model whereas all untreated animals died of the disease. Further, these nanoviricides were superior to topical treatment with an acyclovir formulation employed as a positive control. The company expects that a drug that is superior to existing therapies could result in significantly expanded market size. The nanoviricides prevented the development of scabbing of the herpes virus infected lesions in the animal model. For untreated and sham treated animals, the HSV infection progressed from initial redness at the site of infection to lesions that progressed on the skin along the nerve and internally to ultimately kill the mouse. Topical dermal treatment with these two nanoviricide formulations significantly delayed the onset of the clinical symptoms, prevented the progression of the lesions and produced survival of almost all of the mice (>85%). Existing therapies against HSV include acyclovir and drugs chemically related to it. These drugs must be taken orally or by injection and are not very effective as topical agents. Other drugs are largely ineffective. Currently, there is no cure for herpes infection.

NanoViricides, Inc. announced delayed 10-Q filing

On 02/17/2015, NanoViricides, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NNVC:US $1.56 USD -0.04

NNVC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NNVC.
View Industry Companies
 

Industry Analysis

NNVC

Industry Average

Valuation NNVC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NANOVIRICIDES INC, please visit www.nanoviricides.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.